The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3- carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 1, 2003, Pages 93-102

  Solinas, M ^a   Panlilio, L V ^a   Antoniou, K ^b   Pappas, L A ^a   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DIAMORPHINE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG SELF ADMINISTRATION; ELECTROSTIMULATION; HEROIN DEPENDENCE; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REINFORCEMENT; STIMULUS RESPONSE;

ANALGESICS, OPIOID; ANIMALS; DRUG INTERACTIONS; HALLUCINOGENS; HEROIN; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; SODIUM CHLORIDE; TETRAHYDROCANNABINOL;

EID: 0037937194     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.047928     Document Type: Article

References (39)

1. Arnold JM and Roberts DC (1997) A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57:441-447.
2. Bickel WK, Marsch LA, and Carroll ME (2000) Deconstructing relative reinforcing efficacy and situating the measures of pharmacological reinforcement with behavioral economics: a theoretical proposal. Psychopharmacology 153:44-56.
3. Brebner K, Phelan R, and Roberts DC (2000) Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules. Psychopharmacology 148:314-321.
4. Chaperon F, Soubrie P, Puech AJ, and Thiebot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135:324-332.
5. Cohen C, Perrault G, Voltz C, Steinberg R, and Soubrie P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451-463.
6. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, and Fratta W (2001) Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118:61-65.
7. Deroche-Gamonet V, Le Moal M, Piazza PV, and Soubrie P (2001) SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. Psychopharmacology 157:254-259.
8. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJ, and Schoffelmeer AN (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151-1154.
9. Di Chiara G and Imperato A (1988) Opposite effects of μ and κ opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067-1080.
10. Gardner EL and Lowinson JH (1991) Marijuana's interaction with brain reward systems: update 1991. Pharmacol Biochem Behav 40:571-580.
11. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, and Maldonado R (2002) Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors. J Neurosci 22:1146-1154.
12. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, and Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
13. Giuffrida A and Piomelli D (1998) Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett 422:373-376.
14. Goldberg SR, Munzar P, Justinova Z, and Tanda G (2001) Effects of naltrexone on intravenous self-administration of δ-9-tetrahydrocannabinol (THC) by squirrel monkeys under fixed-ratio and second-order schedules, in Abstracts of the 2001 Symposium on the Cannabinoids, International Cannabinoid Research Society, Burlington, p 102.
15. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
16. Hodos W (1961) Progressive ratio as a measure of reward strength. Science (Wash DC) 134:943-944.
17. Howlett AC (2002) The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69:619-631.
18. Landsman RS, Burkey TH, Consroe P, Roeske WR, and Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1-R2.
19. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (Wash DC) 283:401-404.
20. Maldonado R (2002) Study of cannabinoid dependence in animals. Pharmacol Ther 95:153-164.
21. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, and Fuentes JA (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20:287-294.
22. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, and Koob GF (1993) Animal models of drug craving. Psychopharmacology 112:163-182.
23. Martin M, Ledent C, Parmentier M, Maldonado R, and Valverde O (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12:4038-4046.
24. Matsuda LA, Bonner TI, and Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535-550.
25. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, Maldonado R, et al. (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21:5344-5350.
26. Navarro M, Chowen J, Rocio ACM, del Arco I, Villanua MA, Martin Y, Roberts AJ, Koob GF, and de Fonseca FR (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9:3397-3402.
27. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 54:1064-1072.
28. Panlilio LV and Schindler CW (2000) Self-administration of remifentanil, an ultra-short acting opioid, under continuous and progressive-ratio schedules of reinforcement in rats. Psychopharmacology 150:61-66.
29. Reisine T, Law SF, Blake A, and Tallent M (1996) Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Ann NY Acad Sci 780:168-175.
30. Roberts DC and Bennett SA (1993) Heroin self-administration in rats under a progressive ratio schedule of reinforcement. Psychopharmacology 111:215-218.
31. Rodriguez JJ, Mackie K, and Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21:823-833.
32. Rubino T, Massi P, Vigano D, Fuzio D, and Parolaro D (2000) Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci 66:2213-2219.
33. Singer JD (1998) Using SAS PROC MIXED to fit multilevel models, hierarchical models and individual growth models. J Educ Behav Stat 24:323-355.
34. van Ree JM, Gerrits MA, and Vanderschuren LJ (1999) Opioids, reward and addiction: an encounter of biology, psychology and medicine. Pharmacol Rev 51:341-396.
35. Vasquez C and Lewis DL (1999) The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19:9271-9280.
36. Vinklerova J, Novakova J, and Sulcova A (2002) Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. J Psychopharmacol 16:139-143.
37. Wiley JL, Barrett RL, Lowe J, Balster RL, and Martin BR (1995a) Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669-676.
38. Wiley JL, Lowe JA, Balster RL, and Martin BR (1995b) Antagonism of the discrim-inative stimulus effects of δ9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.
39. Yasar S, Schindler CW, Thorndike EB, Szelenyi I, and Goldberg SR (1993) Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats. J Pharmacol Exp Ther 265:1-6.